Picture Berlin Partner Events Bionnale 2025 May HealthCapital 650x100px

Product › Details

Gazyva® / Gazyvaro®

	Next higher product group	obinutzuzumab
	Status	2013-12-31 registration start
	Organisation	Roche (Group)

Record changed: 2023-07-10

Picture Swiss Biotech Association Swiss Biotech Days 2025 SBD25 Basel 650x200px

More documents for antibody cancer drug

[1] Ottimo Pharma Ltd.. (12/19/24). "Press Release: Ottimo Pharma Raises over $140 Million in Series A Financing". London & Boston, MA....
[2] BioNTech SE. (11/13/24). "Press Release: BioNTech to Acquire Biotheus to Boost Oncology Strategy". Mainz....
[3] Ottimo Pharma Ltd.. (10/28/24). "Press Release: Ottimo Pharma Emerges from Stealth with Backing from Medicxi and Management Team Led by David Epstein to Accelerate Development of a Novel PD1/VEGFR2 Bi-Functional Antibody Planned to Enter the Clinic in 20...
[4] Dren Bio, Inc.. (7/24/24). "Press Release: Dren Bio Announces Strategic Collaboration with Novartis to Develop Novel Targeted Myeloid Engagers for Cancer". Foster City, CA....
[5] Catalym GmbH. (7/16/24). "Press Release: Catalym Announces New Financing of $150M to Support Broad Phase 2b Development Program for Visugromab". Munich....
[6] Apeiron Biologics AG. (7/8/24). "Press Release: Apeiron Biologics to Be Acquired by Ligand Pharmaceuticals for USD 100 Million". Vienna....
[7] Tacalyx GmbH. (6/11/24). "Press Release: Tacalyx Extends Seed Round to over €14 M to Advance Development of its Cancer Therapeutics Targeting TACAs". Berlin....
[8] Jeito Capital. (5/22/24). "Press Release: Jeito Capital Announces Acquisition of Portfolio Company HI-Bio by Biogen Inc. (Nasdaq: BIIB) for up to $1.8 Billion". Paris....
[9] Biogen Inc.. (5/22/24). "Press Release: Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences". Cambridge, MA & South San Francisco, CA....
[10] MorphoSys AG. (2/5/24). "Press Release: MorphoSys Enters into Business Combination Agreement to Be Acquired by Novartis for € 2.7 Billion Equity Value. Tafasitamab Sold to Incyte". Planegg....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)